# Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

> **NCT01888302** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Hepatic Complication

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT01888302
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2016-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888302, "Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01888302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*